2016 Attendee remarks from Faculty and Delegates:
“You can rely on the HEART UK meeting to provide you with the most recent and up-to-date information in the field of clinical Lipidology in the UK and an insight into what is on the horizon.”
“The conference allowed me to present a poster to an audience of experts in the field of lipidology… it was a fantastic learning opportunity.”
“All of it. It is the best source of reliable information on lipid medicine and provides excellent opportunities to network and understand what's happening all over the country.”
“A good opportunity to update knowledge in the field of Lipidology and learn about things that could be applicable at the Clinic and are not just at a research level.”
“Very informative, excellent networking opportunities, suitable for clinicians, nurses and AHP's.”
“Probably best UK event for CPD in lipidology and related fields.”
"Having only been in post as British Heart Foundation Clinical Nurse Specialist in Familial Hypercholesterolaemia (FH) a couple of months, the prospect of attending a conference whereby experts in the field of lipidology, cardiology and FH are abundant was both daunting and exciting. I hoped to put names to faces, to gain a better understanding of the ‘bigger picture’ and to meet people who could stimulate my mind and trigger ideas. I am glad to say all those targets were exceeded but, not only that, the main heartfelt theme that all delegates, speakers and patients together had the same passion for the prevention of Coronary Heart Disease (CHD) was very evident. From professors to patients’, the message was clear, learning from each other and challenging practice for a better life for all, a message which was quite refreshing."
"...the HEART UK Conference taught me that everyone in the field is approachable, we all have the same aim and I look forward to the next conference where I hope to gain a better understanding of the genetics and science behind FH."
For any questions relating to the Annual Conference, please contact the conference office below:
Wheldon Events & Conferences
93 Watling Street, Bridgtown,
Cannock, Staffordshire WS11 0BG
T: +44 (0) 1543 503 322
F: +44 (0) 1543 466 890
Medical & Scientific Programme
"Cholesterol - a problem solved?"
Thursday 6 - Friday 7 July 2017
Presented by leading scientists and healthcare professionals including the keynote Myant lecture, oral abstracts and open and interactive discussion.
This section targets an audience such as hospital doctors, GPs, clinical lipidologists, biochemists and researchers in lipids.
The conference is sponsored by various organisations. These organisations have had no input into the development of the programme for the study day, Medical & Scientific and Healthcare programme’s, or influenced the choice of speakers. But excluding the sponsored symposia sessions where the programme is developed and speakers identified by the sponsor. View full sponsors list
Approved by the Federation of the Royal Colleges of Physicians of the United Kingdom for category 1 (external) CPD credit(s).
Thursday x 6 credits
Friday x 4 credits
British Dietetic Association endorsement approved:
BDA endorsement applies only to the educational content of the learning activity’
PROGRAMME – Thursday 6 July
08:00 Registration opens
08:30–09:15 Refreshments, networking and exhibition
SESSION A: Dyslipidaemia – Progress, opportunities + challenges
Mr Ray EDWARDS, Chairman, HEART UK
Dr Alan REES, Medical Director, HEART UK
Co-chairs: Nigel CAPPS + Elizabeth HUGHES
Improving outcomes through personalised medicine
Ms Fiona CARRAGHER
Deputy Chief Scientific Officer, NHS England, London
Update on FH – the national view
Professor Huon GRAY
National Clinical Director for Heart Disease, NHS England
Consultant Cardiologist, University Hospital of Southampton
Child-Parent Screening for Familial Hypercholesterolaemia
A new approach to population screening for inherited heart disease
Professor David WALD
Professor of Cardiology
Barts and the London School of Medicine and Dentistry, QMUL, London, UK
10:35 – 10:55
Paediatrics – a picture of inherited dyslipidaemias
Dr Uma RAMASWAMI
Consultant in Inherited Metabolic Disorders, Royal Free Hospital, London
11:00-11:30 Refreshments, networking and exhibition
Session B runs in parallel to Session C the Healthcare Programme
Polygenic Familial Hypercholesterolaemia ? – the SNP score explained
Professor Steve HUMPHRIES
UCL, London, UK
The future perspectives for care for patients with high Lp(a)
Professor Erik STROES
University of Amsterdam, Amsterdam, THE NETHERLANDS
The Gut Microbiome in Obesity and Dyslipidaemia
Links between the gut microbiome and obesity are well established and a role in dyslipidaemia is emerging.
Dr Claire STEVES
Deputy Director (Clinical), Department of Twin Research and Genetic Epidemiology;
Senior Clinical Lecturer, King’s College London
Twin Research and Genetic Epidemiology, London, UK
13:15-14:30 Lunch, networking and exhibition
CLINICAL LIPIDOLOGY LIVE!
Audience participation encouraged
Facilitator: Dr Dev DATTA
HEART UK walk
Everyone welcome - come and enjoy this heart healthy exercise
16:00–16:45 Refreshments, networking and exhibition
Chair: Ray EDWARDS, Chairman, HEART UK
HEART UK charity update
Miss Jules PAYNE
Chief Executive, HEART UK
Cholesterol and cardiovascular disease – is diet really relevant?
Professor Tom SANDERS
This lecture will address the importance of reducing the intake of saturated and trans fatty acids for management of LDL cholesterol and what they should be replaced with in the diet in terms of type of unsaturated fatty acids carbohydrates. It will also explain how excess fat accumulation even in the normal weight ranges has adverse effects on lipids and how insulin resistance results in the atherogenic lipoprotein phenotype. It will conclude by discussing current dietary advice for the prevention of CHD and some recent controversies.
18:00 – 18:30
HEART UK AGM
Pre dinner drinks
Conference dinner and dancing
PROGRAMME – Friday 7 July
08:45 – 09:45
Moderated Poster Session
Your chance to vote for your "People's Choice" best poster
09.45 – 09:50
Dr Alan REES, Medical Director, HEART UK
Professor Gary FROST
Imperial College, London, UK
10:35 – 10:50 Discussion
10:50 - 11:20 Refreshments, networking and exhibition
Session F runs in parallel to Session G the Healthcare programme
CV outcome trials for anti-diabetic drugs – where are we now?
Professor Clifford J BAILEY
Professor of Clinical Science, Life and Health Sciences, Aston University, Birmingham, UK
Research funding – what has been done and results
Professor Carol SHOULDERS
SESSION H: Health & Primary Care Abstracts of Free Communications
Session H runs in parallel to Session I the Healthcare Programme
13:20–14:20 Abstracts of Free Communications
13:20 – 13:30
1/ Very low-density lipoprotein associated apolipoproteins predict cardiovascular events and are lowered by inhibition of APOC-III
Yin X*1, Pechlaner R2, Tsimikas S3,4, Baig F1, Haudebourg E1, Witztum JL3, Willeit J2, Kiechl S2, Mayr M1
1 King’s British Heart Foundation Centre, King’s College London, London, UK
2 Department of Neurology, Medical University Innsbruck, Innsbruck, AUSTRIA
3 University of California San Diego, La Jolla, CA, USA
4 Ionis Pharmaceuticals, Carlsbad, CA, USA
13:30 – 13:35 Discussion
13:35 – 13:45
2/ Apolipoprotein C-III inhibition with volanesorsen in patients with hypertriglyceridemia (COMPASS): A randomized, double-blind, placebo-controlled trial
1I Gouni-Berthold, 2V Alexander, 3A Digenio, 4R DuFour, 5E Steinhagen-Thiessen, 6S Martin, 7P Moriarty, 2S Hughes, 3R Jones 2JL Witztum, 8D Gaudet, 9E Stroes for the COMPASS investigators
1Polyclinic for Endocrinology, Diabetes and Preventive Medicine, University of Cologne, Cologne, Germany. 2Ionis Pharmaceuticals, Carlsbad, CA, 3Akcea Therapeutics a Subsidiary of IONIS Pharmaceuticals, Cambridge MA 4 Institut de recherches cliniques de Montréal and Université de Montréal, Montréal QC Canada 5 Charite - University Hospital Berlin -Hospital Lipidambulanz Berlin, Germany, 6 Peterborough City Hospital, Cambridgeshire UK, 7 University of Kansas Medical Center, Lawrence Kansas 8 Dept of Medicine, Université de Montréal, Chicoutimi, QC, Canada 9 Dept. Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
13:45 – 13:50 Discussion
13:50 – 14:00
3/ Meta-analysis of the effect of intensive cholesterol reduction on numbers needed to treat to prevent cardiovascular events in 75,439 participants in 10 randomised controlled clinical trials
Safwaan Adam1,2*, Handrean Soran1,2, See Kwok1,2, Jan Hoong Ho1,2, Paul N Durrington1
1Cardiovascular Research Group, University of Manchester
2Cardiovascular Trials Unit, Central Manchester University Hospitals NHS Trust, UK
14:00 – 14:05 Discussion
14:05 – 14:15
4/ Can the nocebo effect explain statin related muscle symptoms without CK elevation?
Bakar NS 1, Neely RDG* 2, Avery P 3, Brown C 4, Daly AK 1, Kamali F 1.
1Institute of Cellular Medicine, Newcastle University, 2Blood Sciences, Newcastle upon Tyne Hospitals Foundation Trust; 3School of Mathematics and Statistics, Newcastle University, 4Institute for Cell and Molecular Biosciences, Newcastle University.
14:15 – 14:20 Discussion
14:20-14:30 Comfort break
Presentation of prizes and awards
COURTROOM DRAMA - an interactive session:
Sanofi have sponsored this session as part of their premium sponsorship. They have had no input into the content, the speaker selection or topic selection.
Current treatments – that’s cholesterol sorted then !
THE CHARGE: With new treatments LDL is now sorted
Judge: Professor Elizabeth HUGHES, Birmingham
15:40 Conference close